Pharmaceutical giant AstraZeneca has expanded its artificial intelligence-driven collaboration with biotech company Immunai, deepening a multi-year partnership focused on advancing oncology drug development. Under the latest agreement, Immunai could receive up to US$37.5 million during 2026 and 2027 as AstraZeneca continues integrating the startup’s AI-powered immune system platform into its clinical research programs.
The expanded collaboration will allow AstraZeneca to further use Immunai’s AMICA-OS platform, an artificial intelligence operating system designed to model the human immune system using large-scale clinical immunology data at single-cell resolution. The platform combines advanced AI models with biological datasets to generate insights that support cancer research, biomarker discovery, patient selection, dose optimization, and treatment-response analysis.
The partnership between the two companies originally began in 2024 with a focus on oncology clinical programs. In 2025, the collaboration expanded into inflammatory bowel disease research, reflecting AstraZeneca’s growing interest in applying AI technologies across multiple therapeutic areas. The latest extension now broadens the oncology-focused work through 2027, signalling continued confidence in Immunai’s technology and research capabilities.
Immunai, a New York-headquartered biotech firm founded by Israeli entrepreneurs, has been building what it describes as a comprehensive “map of the immune system.” The company’s AI infrastructure is designed to help pharmaceutical firms better understand how immune cells behave in diseases and respond to treatments. By analysing complex biological data, the platform aims to reduce costly late-stage drug development failures and improve the success rate of clinical trials.
Industry analysts believe the agreement highlights the increasing role of artificial intelligence in pharmaceutical research and drug discovery. Major pharmaceutical companies are rapidly adopting AI-powered platforms to accelerate clinical development, improve precision medicine strategies, and shorten timelines for bringing new therapies to market. Experts say collaborations like the AstraZeneca-Immunai partnership could become increasingly common as the healthcare industry invests heavily in AI-driven biomedical innovation.
